Deciphera Pharmaceuticals’ (DCPH) Market Perform Rating Reiterated at JMP Securities

JMP Securities restated their market perform rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a report released on Tuesday, Benzinga reports.

Other analysts have also recently issued research reports about the stock. Jefferies Financial Group reissued a hold rating and set a $25.60 price target (down previously from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. Jonestrading reissued a hold rating and issued a $25.60 price target on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. Barclays raised Deciphera Pharmaceuticals from an underweight rating to an equal weight rating and upped their price objective for the stock from $9.00 to $26.00 in a research report on Tuesday. Stifel Nicolaus lifted their target price on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a buy rating in a report on Wednesday, February 7th. Finally, JPMorgan Chase & Co. boosted their target price on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a neutral rating in a research note on Wednesday, March 20th. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Hold and an average price target of $24.17.

Deciphera Pharmaceuticals Price Performance

Shares of NASDAQ DCPH opened at $25.38 on Tuesday. The business’s 50 day moving average is $16.56 and its two-hundred day moving average is $14.80. Deciphera Pharmaceuticals has a 52-week low of $9.90 and a 52-week high of $25.47. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of -11.08 and a beta of 0.20.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The firm had revenue of $48.30 million for the quarter, compared to the consensus estimate of $45.93 million. During the same quarter in the previous year, the business earned ($0.60) EPS. The company’s quarterly revenue was up 32.9% compared to the same quarter last year. Analysts anticipate that Deciphera Pharmaceuticals will post -2.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Deerfield Management Company L.P. Series C lifted its holdings in Deciphera Pharmaceuticals by 2.8% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock worth $87,738,000 after buying an additional 190,580 shares during the last quarter. Armistice Capital LLC lifted its stake in Deciphera Pharmaceuticals by 12.7% during the fourth quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $83,876,000 after purchasing an additional 588,000 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Deciphera Pharmaceuticals by 14.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company’s stock valued at $37,220,000 after purchasing an additional 290,968 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Deciphera Pharmaceuticals by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,561,654 shares of the company’s stock valued at $25,191,000 after purchasing an additional 92,410 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. raised its holdings in Deciphera Pharmaceuticals by 176.2% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company’s stock worth $16,482,000 after purchasing an additional 651,800 shares in the last quarter. Hedge funds and other institutional investors own 70.96% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.